Skip to main content
Top
Published in: Gastric Cancer 1/2020

01-01-2020 | Gastric Cancer | Original Article

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

Authors: Simon Pernot, Magali Terme, Nina Radosevic-Robin, Florence Castan, Cécile Badoual, Elie Marcheteau, Fréderique Penault-Llorca, Olivier Bouche, Jaafar Bennouna, Eric Francois, Francois Ghiringhelli, Christelle De La Fouchardiere, Emmanuelle Samalin, Jean Baptiste Bachet, Christophe Borg, Valérie Boige, Thibault Voron, Trevor Stanbury, Eric Tartour, Sophie Gourgou, David Malka, Julien Taieb

Published in: Gastric Cancer | Issue 1/2020

Login to get access

Abstract

Background

The correlation between immune cells and the Lauren classification subtypes and their prognostic impact in advanced gastric cancer (AGC) are unknown.

Methods

Circulating natural killer (NK) cells, CD4+ and CD8+ T cells, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) were quantified in peripheral blood mononuclear cells (PBMCs) from 67 patients with untreated AGC enrolled in the PRODIGE 17-ACCORD 20 trial. CD56+ cells (NK), CD8+, and FoxP3+ (Treg) tumor-infiltrating lymphocytes (TILs) were assessed in tumor samples.

Results

Circulating NK and Treg proportions were significantly lower in patients with diffuse/mixed-type AGC (n = 27) than those with intestinal type (n = 40; median 6.3% vs 11.5%; p = 0.02 and median 3.3% vs 5.2%; p = 0.03, respectively). Proportions of circulating MDSC, CD4+ and CD8+ T cells were not associated with one pathological type. Among tumor-infiltrating cells, CD8+ T cells, but not NK or FoxP3+ cells, were significantly lower in diffuse/mixed-type AGC (median 21 vs 59 cells/field; p = 0.009). Patients with high circulating NK cell counts (> 17%) had a better overall survival than those with < 17% (HR 0.40; 95% CI [0.15–1.06]; p = 0.04). Patients with high CD8+ TIL counts (> 31 cells/field) had significantly longer overall survival (HR 0.44; 95% CI [0.21–0.92]; p = 0.02). The prognostic value of CD8+ TILs was maintained after adjustment for confounding factors, including the Lauren classification (HR = 0.42; 95% CI [0.18–0.96]; p = 0.039).

Conclusion

Diffuse/mixed-type AGC has lower rates of CD8+ TILs and circulating NK cells and Tregs than the intestinal type. This “cold tumor” phenotype may be associated with a worse outcome.
Appendix
Available only for authorised users
Literature
6.
go back to reference Arigami T, Uenosono Y, Ishigami S, Matsushita D, Hirahara T, Yanagita S, et al. Decreased density of CD3+ tumor-infiltrating lymphocytes during gastric cancer progression. J Gastroenterol Hepatol. 2014;29:1435–41.CrossRefPubMed Arigami T, Uenosono Y, Ishigami S, Matsushita D, Hirahara T, Yanagita S, et al. Decreased density of CD3+ tumor-infiltrating lymphocytes during gastric cancer progression. J Gastroenterol Hepatol. 2014;29:1435–41.CrossRefPubMed
12.
go back to reference Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.CrossRef Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;390:2461–71. https://​doi.​org/​10.​1016/​S0140-6736(17)31827-5.CrossRef
13.
go back to reference Shitara K, Özgüroğlu M, Bang Y-J, Di Bartolomeo M, Mandalà M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet Lond Engl. 2018;392:123–33. https://doi.org/10.1016/S0140-6736(18)31257-1.CrossRef Shitara K, Özgüroğlu M, Bang Y-J, Di Bartolomeo M, Mandalà M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet Lond Engl. 2018;392:123–33. https://​doi.​org/​10.​1016/​S0140-6736(18)31257-1.CrossRef
15.
go back to reference Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed
22.
go back to reference Malka D, Castan F, Francois E, Bouche O, Bennouna J, Ghiringhelli F, et al. FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): an open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). J Clin Oncol. 2015;33:4013–4013. https://doi.org/10.1200/jco.2015.33.15_suppl.4013.CrossRef Malka D, Castan F, Francois E, Bouche O, Bennouna J, Ghiringhelli F, et al. FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): an open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). J Clin Oncol. 2015;33:4013–4013. https://​doi.​org/​10.​1200/​jco.​2015.​33.​15_​suppl.​4013.CrossRef
24.
go back to reference Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: prognostic value and early assessment of therapeutic effects. Eur J Cancer Oxf Engl. 1990;2017(79):15–22. https://doi.org/10.1016/j.ejca.2017.03.036.CrossRef Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: prognostic value and early assessment of therapeutic effects. Eur J Cancer Oxf Engl. 1990;2017(79):15–22. https://​doi.​org/​10.​1016/​j.​ejca.​2017.​03.​036.CrossRef
28.
go back to reference Teh M, Lee YS. HLA-DR antigen expression in intestinal-type and diffuse-type gastric carcinoma. Cancer. 1992;69:1104–7.CrossRefPubMed Teh M, Lee YS. HLA-DR antigen expression in intestinal-type and diffuse-type gastric carcinoma. Cancer. 1992;69:1104–7.CrossRefPubMed
34.
go back to reference Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30:83–95. https://doi.org/10.1007/s10555-011-9281-4.CrossRefPubMed Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30:83–95. https://​doi.​org/​10.​1007/​s10555-011-9281-4.CrossRefPubMed
35.
go back to reference Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2:1679–84.PubMed Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2:1679–84.PubMed
36.
go back to reference Ohtani H, Nagura H. Differing microvasculature in the two major types of gastric carcinoma: a conventional, ultrastructural and ultrastructural immunolocalization study of von Willebrand factor. Virchows Arch A Pathol Anat Histopathol. 1990;417:29–35.CrossRefPubMed Ohtani H, Nagura H. Differing microvasculature in the two major types of gastric carcinoma: a conventional, ultrastructural and ultrastructural immunolocalization study of von Willebrand factor. Virchows Arch A Pathol Anat Histopathol. 1990;417:29–35.CrossRefPubMed
37.
go back to reference Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 2017;153(191–204):e16. https://doi.org/10.1053/j.gastro.2017.03.046.CrossRef Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 2017;153(191–204):e16. https://​doi.​org/​10.​1053/​j.​gastro.​2017.​03.​046.CrossRef
39.
go back to reference Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88:577–83.CrossRefPubMed Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88:577–83.CrossRefPubMed
40.
go back to reference Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett. 2000;159:103–8.CrossRefPubMed Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett. 2000;159:103–8.CrossRefPubMed
41.
go back to reference Rosso D, Rigueiro MP, Kassab P, Ilias EJ, Castro OAP, Novo NF, et al. Correlation of natural killer cells with the prognosis of gastric adenocarcinoma. Arq Bras Cir Dig ABCD Braz Arch Dig Surg. 2012;25:114–7.CrossRef Rosso D, Rigueiro MP, Kassab P, Ilias EJ, Castro OAP, Novo NF, et al. Correlation of natural killer cells with the prognosis of gastric adenocarcinoma. Arq Bras Cir Dig ABCD Braz Arch Dig Surg. 2012;25:114–7.CrossRef
42.
go back to reference Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018;66:15–22.CrossRefPubMedPubMedCentral Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018;66:15–22.CrossRefPubMedPubMedCentral
Metadata
Title
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance
Authors
Simon Pernot
Magali Terme
Nina Radosevic-Robin
Florence Castan
Cécile Badoual
Elie Marcheteau
Fréderique Penault-Llorca
Olivier Bouche
Jaafar Bennouna
Eric Francois
Francois Ghiringhelli
Christelle De La Fouchardiere
Emmanuelle Samalin
Jean Baptiste Bachet
Christophe Borg
Valérie Boige
Thibault Voron
Trevor Stanbury
Eric Tartour
Sophie Gourgou
David Malka
Julien Taieb
Publication date
01-01-2020
Publisher
Springer Singapore
Published in
Gastric Cancer / Issue 1/2020
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-019-00983-3

Other articles of this Issue 1/2020

Gastric Cancer 1/2020 Go to the issue